<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00225095</url>
  </required_header>
  <id_info>
    <org_study_id>Osiris 550</org_study_id>
    <nct_id>NCT00225095</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy</brief_title>
  <official_title>A Phase I/II, Randomized, Controlled, Double Blind, Study of Chondrogen - Adult Universal Cell Delivered by Intra-Articular Injection Following Meniscectomy in Patients 18-60 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mesoblast International SÃ rl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Midwest Orthopedics at Rush - Chicago, IL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Unlimited Research - San Antonio, TX</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triangle Orthopaedic Associates, P.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orthopedic Center of Vero Beach - Vero Beach, FL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>OrthoIndy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TRIA Orthopaedic Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Greater Chesapeake Associates - Baltimore, MD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mesoblast, Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Chondrogen is a safe and effective
      post-operative treatment of the knee following menisectomy (the surgical removal of all or
      part of a torn meniscus).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chondrogen is a preparation of adult mesenchymal stem cells (MSCs) in a solution containing
      hyaluronic acid. Preclinical studies have shown that injection of Chondrogen aids in the
      repair of meniscal tissue following meniscectomy. In Chondrogen treated subjects, surgically
      removed meniscal tissue was regenerated, cartilage surface was protected, and joint damage
      was decreased in comparison to control subjects. These benefits persisted at least one year.

      Three groups of recent meniscectomy patients will be followed in this study, including
      patients that will receive placebo and patients that will be treated with one of two possible
      doses of Chondrogen.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>meniscal volume</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immunological endpoints</measure>
    <time_frame>Baseline to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Recovery Following Partial Medial Meniscectomy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chondrogen dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Chondrogen dose 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesenchymal Stem Cells</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyaluronan</intervention_name>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 60, inclusive

          -  In need of medial meniscectomy

          -  Normal axial alignment

          -  Stable knee- previous ligament reconstruction, if stable

          -  Removal of at least 50% of the affected portion of the medial meniscus

          -  Intact articular cartilage in posterior meniscal weight-bearing zone

          -  Willingness to follow normal post-operative rehabilitation

          -  Willingness to participate in follow-up for two years from the time of meniscectomy
             surgery

          -  Ability to understand and willingness to sign consent form

        Exclusion Criteria:

          -  Pregnant or lactating

          -  ACL or other support structure damage confirmed at surgery

          -  Grade III or IV cartilage damage (Cartilage loss greater than 50% thickness in area
             &gt;15mm on weight-bearing aspect of femoral condyle or tibial plateau)

          -  Synvisc, steroid, or corticosteroid injections in preceding 3 months

          -  Diffuse synovitis at time of arthroscopy

          -  Inflammatory arthritis

          -  Oral steroid, methotrexate therapy

          -  Unable to follow post-operative exercise regimen or return for evaluations

          -  Active alcohol or substance abuse within 6 months of study entry

          -  Current and active tobacco product use

          -  Patient is positive for HIV

          -  Patient is positive for hepatitis (past history of Hepatitis A is allowed)

          -  Any medical condition, which in the opinion of the clinical investigator, would
             interfere with the treatment or outcome of the patient

          -  Indwelling pacemaker

          -  Cerebral aneurysm clips

          -  Ear, eye and penile implants with avian components

          -  Electrical indwelling device such as bone stimulator

          -  Indwelling magnets as tissue expander for future implants

          -  Known allergy to avian, bovine or porcine protein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Williams, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Osiris Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic Center of Vero Beach</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Orthopaedics at Rush</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortholndy</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Chesapeake Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TRIA Orthopaedic Center</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triangle Orthopaedics Associates, P.A.</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unlimited Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.osiristx.com</url>
    <description>Osiris Therapeutics, Inc. Home Page</description>
  </link>
  <reference>
    <citation>Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7.</citation>
    <PMID>10102814</PMID>
  </reference>
  <reference>
    <citation>Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003 Dec;48(12):3464-74.</citation>
    <PMID>14673997</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2005</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>meniscectomy</keyword>
  <keyword>Chondrogen</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Osiris</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

